Document Detail

1070 myeloablative megatherapy procedures followed by stem cell rescue for neuroblastoma: 17 years of European experience and conclusions. European Group for Blood and Marrow Transplant Registry Solid Tumour Working Party.
MedLine Citation:
PMID:  9516868     Owner:  NLM     Status:  MEDLINE    
1070 myeloablative procedures followed by stem cell rescue for neuroblastoma are reviewed. These 1070 procedures are part of the European Group for Blood and Marrow Transplant (EBMTG) registry from the last 17 years (in 4536 patients). In 1070 neuroblastoma patients, survival at 2 years was 49%, at 5 years, 33% and relapses were observed as late as 7 years post-BMT (bone marrow transplant). However, 5-year survivors after megatherapy with BMT for stage 4 disease do have an 80% chance of becoming a long-term survivor. When BMT had been used in first complete response (CR1) no salvage was possible, whereas 15% survivors may be seen if BMT is used for the first time at relapse. Infants with stage 4 neuroblastoma had a 17% toxic death rate and indication in this group is exceptional and not recommended. In a matched cohort (17 allogeneic and 34 autologous), autologous stem cell rescue (SCR) was shown to be at least equal to allogeneic SCR. Multivariate analysis of clinical prognostic factors in children with stage 4 disease over 1 year showed that event-free survival was mainly influenced by two adverse factors before the megatherapy procedure: persisting skeleton lesions (99Tc and/or mIBG scan positive) as well as persisting bone marrow (BM) involvement.
T Philip; R Ladenstein; C Lasset; O Hartmann; J M Zucker; R Pinkerton; A D Pearson; T Klingebiel; A Garaventa; B Kremens; J L Bernard; G Rosti; F Chauvin
Related Documents :
24557608 - Liver surgery and transplantation in china: progress and challenges.
1926348 - Recovery of monocytes after bone marrow transplantation--rapid reappearance of tumor ne...
9175318 - Early detection of bone marrow engraftment by amplification of hypervariable dna regions.
11753548 - Second bone marrow transplantation for severe aplastic anemia: analysis of 34 cases.
353558 - The social and economic cost of end-stage renal disease. a patient's perspective.
15646438 - Ethical guidelines for the evaluation of living organ donors.
Publication Detail:
Type:  Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  European journal of cancer (Oxford, England : 1990)     Volume:  33     ISSN:  0959-8049     ISO Abbreviation:  Eur. J. Cancer     Publication Date:  1997 Oct 
Date Detail:
Created Date:  1998-03-31     Completed Date:  1998-03-31     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  9005373     Medline TA:  Eur J Cancer     Country:  ENGLAND    
Other Details:
Languages:  eng     Pagination:  2130-5     Citation Subset:  IM    
Centre Léon Bérard, Department of Paediatrics, Lyon, France.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Case-Control Studies
Child, Preschool
Combined Modality Therapy
Follow-Up Studies
Hematopoietic Stem Cell Transplantation / statistics & numerical data*
Infant, Newborn
Multivariate Analysis
Neuroblastoma / therapy*
Registries / statistics & numerical data*
Retrospective Studies
Risk Factors
Survival Analysis
Transplantation Conditioning*
Transplantation, Autologous
Transplantation, Homologous / adverse effects
Treatment Outcome

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Stage IV neuroblastoma in patients over 1 year of age at diagnosis: consolidation of poor responders...
Next Document:  Liver stem cells: when the going gets tough they get going.